<DOC>
	<DOCNO>NCT02714530</DOCNO>
	<brief_summary>The purpose study determine erlotinib give orally along concurrent palliative irradiation lung cancer improve local control compare treated radiotherapy alone .</brief_summary>
	<brief_title>Thoracal Radiotherapy Tarceva</brief_title>
	<detailed_description>Endpoints : Primary : - To determine erlotinib give orally along concurrent external beam radiation therapy , prolongs local tumour control determine CT evaluation compare treatment external beam radiation therapy alone Secondary : - To confirm safety profile erlotinib along concurrent external beam radiation therapy . - To evaluate erlotinib along concurrent external beam radiation therapy , improve quality life assess EORTC QLQ-C30 EORTC QLQ-LC13 . - To evaluate PET-CT examination use predict response treatment . - To evaluate overall survival different group Trial Design : Open multicenter two-armed randomized phase II trial .</detailed_description>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age &gt; 18 year Histological cytological verify NSCLC Palliative radiotherapy thorax indicate ECOG Performance status 02 Fertile patient must use contraception Signed inform consent Ability understand fill QoL questionnaires Capability take per os medication Serum bilirubin &lt; 2 time upper limit normal ( ULN ) AST ALT &lt; 2 time ULN ( &lt; 5 time ULN liver metastasis present ) Creatinine &lt; 5 time ULN Pregnancy nursing Other prior concurrent malignant disease likely interfere study treatment comparison No evidence significant laboratory find concurrent uncontrolled medical illness , opinion investigator , would interfere study treatment result comparison render patient high risk treatment complication No prior radiotherapy organ / place No concurrent treatment experimental drug Known brain metastasis need radiotherapy Known hypersensitivity erlotinib substance erlotinib tablet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>